Business Description
Renovaro Inc
NAICS : 325414
SIC : 2834
ISIN : US29350E1047
Description
Renovaro Inc formerly Renovaro Biosciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -43.1 | |||||
| 3-Year EPS without NRI Growth Rate | -11.8 | |||||
| 3-Year FCF Growth Rate | 3 | |||||
| 3-Year Book Growth Rate | -41.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.92 | |||||
| 9-Day RSI | 24.49 | |||||
| 14-Day RSI | 32.21 | |||||
| 6-1 Month Momentum % | 1.42 | |||||
| 12-1 Month Momentum % | 169.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | |||||
| Quick Ratio | 0.17 | |||||
| Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.1 | |||||
| Shareholder Yield % | -0.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -76.39 | |||||
| ROA % | -61.93 | |||||
| ROIC % | -30.67 | |||||
| ROC (Joel Greenblatt) % | -2818.16 | |||||
| ROCE % | -73.19 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.31 | |||||
| EV-to-EBIT | -7.39 | |||||
| EV-to-EBITDA | -7.41 | |||||
| EV-to-FCF | -27.5 | |||||
| Earnings Yield (Greenblatt) % | -13.54 | |||||
| FCF Yield % | -3.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Renovaro Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.648 | ||
| Beta | 0.87 | ||
| Volatility % | 348.95 | ||
| 14-Day RSI | 32.21 | ||
| 14-Day ATR (€) | 0.13106 | ||
| 20-Day SMA (€) | 2.3539 | ||
| 12-1 Month Momentum % | 169.81 | ||
| 52-Week Range (€) | 0.36 - 4.84 | ||
| Shares Outstanding (Mil) | 143.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Renovaro Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Renovaro Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Renovaro Inc Frequently Asked Questions
What is Renovaro Inc(STU:2Q5)'s stock price today?
The current price of STU:2Q5 is €1.88. The 52 week high of STU:2Q5 is €4.84 and 52 week low is €0.36.
When is next earnings date of Renovaro Inc(STU:2Q5)?
The next earnings date of Renovaro Inc(STU:2Q5) is 2024-05-10 Est..
Does Renovaro Inc(STU:2Q5) pay dividends? If so, how much?
Renovaro Inc(STU:2Q5) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers